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SEARCHING FOR ENDOPHENOTYPES:  
NEGATIVE SYMPTOMS AND SCHIZOPHRENIA 
Emily B. Maier, BPhil  
University of Pittsburgh, 2014 
 
Schizophrenia is a disorder affecting millions of individuals, with a prevalence rate over one 
percent. Although the diagnosis of schizophrenia has a high heritability, identification of 
individual risk variants has been difficult, due to their small individual effects on the diagnosis. 
Identification of useful endophenotypes - that is, features more sensitive to genetic effects than 
the diagnosis itself - should aid in detecting genetic variants that contribute to the disorder. The 
current study examined negative symptoms as a possible endophenotype for schizophrenia. 
Specifically, the study examined the genetic correlations between the Scale for the Assessment 
of Negative Symptoms (SANS) and schizophrenia among multigenerational, multiplex 
schizophrenia families. To examine diagnostic specificity, major depressive disorder and 
substance abuse were also tested for genetic correlations with negative symptoms. The total 
sample (493) included 43 families, 90 schizophrenia patients, 359 of their relatives, and 44 
controls. The majority of SANS scales were significantly heritable (average h2 = 0.48). Results 
suggested that even among relatives without any diagnoses, the prevalence of negative 
symptoms increased significantly with the degree of genetic relationship to schizophrenia 
(average RG = 0.76) but not depression or substance abuse. This suggests the potential utility of 
negative symptoms as a candidate endophenotype with some diagnostic specificity in studies 
seeking to identify genetic risk variants contributing to schizophrenia.  
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1.0 INTRODUCTION 
 
 
First proposed by Emil Kraeplin (Kraepelin, 1919), schizophrenia, characterized by a severe 
disruption in basic human attributes such as thought, language, perception, emotion and self, 
affects more than one percent of the world’s population, including over 3 million Americans at a 
cost of $62 billion a year (Knapp et al., 2004).  Treatment for the disorder primarily consists of 
pharmacotherapies that often but not always reduce the psychotic symptoms of the disorder. In 
contrast, few pharmacotherapies impact the cognitive and emotional disruptions that are present, 
causing patients to have extreme difficulty assimilating into society, attaining employment, and 
maintaining social relationships. Mortality due to natural and unnatural causes is also 
considerable, and the projected lifespan for individuals with schizophrenia is some 15 years less 
than the general population, largely due to the comorbidity with drug abuse, poverty, and other 
health risks (Crump et al., 2013).   
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1.1 SCHIZOPHRENIA AND VULNERABILITY 
 
1.1.1 Genetic Influence   
 
 
 Numerous epidemiological studies have shown a heritability of approximately 80% for the 
schizophrenia diagnosis (Cardno et al., 1999; Sullivan et al., 2003). This reflects the observation 
that the risk of developing schizophrenia in family members increases with the degree of genetic 
relatedness to the patient – greater risks are associated with higher levels of shared genes. First-
degree relatives (e.g. siblings, dizygotic (DZ) twins) of patients share 50% of their genetic 
variation and show a risk of about 9%. Monozygotic (MZ) co-twins of schizophrenia patients 
share 100% of genetic variation and present risks near 50% (Fischer, 1971; Gottesman & 
Bertelsen, 1989).   
  It is also clear that this high heritability is not due to one gene solely responsible for the 
diagnosis; rather, it is the combined effect of many genes, each with a small effect (O'Donohue 
et al., 2007; O'Donovan et al., 2003; Pogue-Geile & Gottesman, 1999). For example, recently 
several thousand SNPs were reported to be implicated in the etiology of schizophrenia (Purcell, 
2009). In addition to these multiple common genetic variants with small effects, there also 
appear to be rare variants with large effects (Stefansson et al., 2008).    
  The question of importance thus becomes one of identifying such individual genetic 
variants of small effect. One approach to this is through increasing study sample size, thus 
creating an increase in statistical power. As one example of this strategy, in 2013 a genome-wide 
association study identified 13 new risk loci for schizophrenia (Ripke et al., 2013). Part of this 
study’s success was due to the sheer size of the sample: 5,001 cases and 6,243 controls, followed 
up with meta-analyses of another 8,000 patients. A second tactic to detect small genetic effects is 
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to improve the quality of measurement. A measurement that is imprecise may fail to detect the 
differences between two groups, while a precise measurement would reveal significant 
differences.   
 
1.1.2 Endophenotype (Improving the Measurement)  
 
One way to improve the measurement for the purpose of detecting genetic effects is through the 
use of “endophenotypes” (Gottesman & Gould, 2003; Gottesman & Shields, 1972). The idea of 
an endophenotype is that it is more sensitive to genetic effects than is the diagnosis itself. By 
identifying useful endophenotypes, researchers should be in a position to more easily identify the 
genetic variants that contribute to the disorder (Gottesman & Gould, 2003; Tsuang et al., 2000). 
The goal of the endophenotype is that of higher statistical power: certain genes may contribute to 
the diagnosis but do not usually produce clinical symptoms (Moldin, 1994; Tarbox et al., 2012). 
A related endophenotype issue is specificity; in other words, one must differentiate if a liability 
gene has been detected, or if the endophenotype is only discerning the causes of more 
generalized deficits (which could include the target deficit; Faraone et al., 1995).   
How then should such potential endophenotypes be identified? As originally formulated, 
an endophenotype would occur in both monozygotic twins, even those discordant for the 
diagnosis (Gottesman & Shields, 1972). Such an indicator would thus be more common in the 
unaffected relatives of patients than the controls (who are unrelated to a proband). The 
observation that abnormalities are present among relatives who do not have the diagnosis 
suggests that such characteristics are more sensitive to risk gene variants than is the diagnosis 
itself. Numerous studies have demonstrated neuropsychological deficits and behavioral patterns 
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falling below the threshold of a clinical diagnosis among relatives of schizophrenic patients 
(Faraone et al., 1995; Faraone et al., 2000; Katsanis et al., 1990; Thompson et al., 2005). 
Additional studies have also observed such traits in children of schizophrenia parents that are 
similar to, but less severe than those of schizophrenia patients (Davalos et al., 2004; Davies et 
al., 1998; Tarbox et al., 2012; Tarbox & Pogue-Geile, 2008).  
The question then becomes, “Where to look for possible endophenotypes?” It has been 
proposed that symptoms, in essence the same as those observed in individuals with the 
schizophrenia diagnosis, can also be measured at subclinical levels in individuals without 
schizophrenia in the general population (Tarbox et al., 2012). The concept of a disorder 
continuum implies that schizophrenia is not a categorical disorder, but rather the extreme 
expression of otherwise more or less continuously distributed traits in the population. The 
symptoms of schizophrenia can generally be divided into three categories: positive, negative, and 
cognitive, based on factor analyses.   
 
1.1.3 Three Dimensions   
 
Positive symptoms include hallucinations and delusions (American Psychiatric Association, 
DSM-5 Task Force., 2013). These symptoms are “excessive” psychotic behaviors typically not 
seen in healthy patients. Conversely, negative symptoms are aspects or traits that are reduced in 
patients with schizophrenia as compared to the general population. These include flattened 
affect, social withdrawal, speech poverty and anhedonia (Andreasen et al., 1994; Andreasen & 
Olsen, 1982; Bassett et al., 1993; Eaton et al., 1995; Lewine et al., 1983; Peralta et al., 1992; 
Walker & Harvey, 1986). For example, patients may have masked facies, with blank or restricted 
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emotional expressions. Lastly, cognitive impairments such as deficits in working memory and 
attention exist (Cannon et al., 1994; Thompson et al., 2005). However, current pharmacological 
treatments, such as antipsychotic medications, for schizophrenia only address the positive 
symptoms.  Unfortunately, such antipsychotic medications – either typical or atypical – have 
little or no effect upon the negative or cognitive symptomology. 
Negative symptoms, more than positive symptoms, have a significant association with 
functional outcomes and quality of life for individuals with schizophrenia. Negative symptoms 
also tend to be more persistent compared to the more episodic nature of positive symptoms. 
These negative traits have been correlated with cognitive problems, as well as being prognostic. 
For these reasons, negative symptoms are good candidates for a potentially useful 
endophenotype.   
Identification of endophenotypes that correlate with familial risk is a crucial tactic for 
better detecting genetic variation related to the development of schizophrenia. Based on this, the 
current study examined negative symptoms’ sensitivity to schizophrenia familial liability and 
explored their potential as endophenotypes. We are not the first to examine negative symptoms, 
although only a small number of studies have studied their presence among relatives of 
schizophrenia probands. Next we will review and evaluate the work of our predecessors.   
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1.2 LITERATURE REVIEW 
 
 “Negative symptoms” is a term that has many meanings and measurements and has been 
variably used from study to study, as well as over time. Such symptoms have been assessed with 
a variety of measures: the Brief Psychiatric Rating Scale (BPRS) anergia factor (Overall &  
Gorham, 1962); Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1989) and 
Positive and Negative Symptom Scale (PANSS) (Kay et al., 1987) for example.  Here, we will 
restrict the literature review only to studies that have employed either the SANS or a similar 
behavior rating scale of negative symptoms.   
 
1.2.1 Methodological Considerations  
 
Throughout the literature, there are several methodological points that must be considered. First, 
there is often a lack of distinction in how studies group first-degree relatives; some combine 
parents and siblings, while others keep them separate (which is preferable). Second, only a few 
studies report that raters were blind to participants’ status (relatives or controls). Third, often 
studies neglect to state from where the controls were selected; others lack details on the 
screening process. The exclusion criteria for the control groups have also often been stricter than 
for the relatives of patients, creating potentially different comparison group characteristics. 
Potential “healthy” controls are often screened for all psychiatric disorders, leading to the 
possibility that the control group is completely free of any diagnoses. This creates a problem if 
the relatives had any diagnosis, but were being compared to dissimilar controls, potentially 
leading to artifactual results. A “supernormal” control group could thus produce an inflated 
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effect size (Tarbox et al., 2012). In addition, diagnostic specificity is rarely investigated with few 
studies of negative symptoms among relatives of depressed or other diagnosed probands.   
 
1.2.2 Review of Schizophrenia Symptoms in Relatives  
 
Table 1 presents the seven studies of behavior ratings of negative symptoms among relatives of 
schizophrenic probands. The majority of the studies (six), seen in Table 1, imply a genetic 
correlation between negative symptoms and relatives of schizophrenia probands (Chen et al., 
2009; Delawalla et al., 2006; Fanous et al., 2001; Kendler et al., 1993, 1993; Scala et al., 2012; 
Smith et al., 2008).  The one study (Craver et al., 1999) with non-significant effects used a 
modified version of the SANS scale: the Avolition-Apathy, Anhedonia-Asociality, and Attention 
scales were excluded, and certain components of the Affective Flattening (inappropriate affect 
and affective nonresponsivity) and Alogia (poverty of content of speech) scales were removed. 
Additionally, the sample size was smaller than most of the other studies reviewed.  Chen’s article 
was perhaps the most informative, as it not only provided correlations but also estimated the 
heritability of negative symptoms. The study discussed the possibility of genetic components that 
affect both negative symptoms and certain neurocognitive deficits (Chen et al., 2009).   
 
1.2.3 Limitations  
 
It is worth noting that in the literature, the composition of the relatives group varies.  
Three studies used first-degree relatives, with no discrimination between parents and siblings. 
One study did not differentiate between degrees of relationship to the proband, while four 
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articles reported comparison based only on siblings. Furthermore, although most studies did 
match controls to relatives on age and sex to minimize group differences, only six studies 
included relatives of control probands, and none of the studies made use of more distant relatives 
as a comparison group.  
Another potential limitation found in numerous articles was that of a wide age range. 
Although the average age of a relative was generally in the 40s and 50s, some subjects were as 
young as 18 – an age still within the risk for developing schizophrenia. Thus, individuals could 
have been misclassified; if researchers had followed up these individuals, some could have 
developed schizophrenia. Although only explicitly mentioned in the Bassett article, there may 
also have been incidences of rater bias, especially if diagnostic interviews and symptom 
assessments were done simultaneously or by the same individuals across relatives. Craver’s 
study excluded portions of the SANS scale in analysis, and found that there was not a 
relationship between these negative symptoms and relatives (Craver & Pogue-Geile, 1999).   
 
1.2.4 Summary of the Review  
 
The data reviewed above generally supported the idea of a genetic correlation between negative 
symptoms and schizophrenia, based on comparisons between first-degree relatives of 
schizophrenia patients and psychiatrically healthy controls. Certain negative symptoms (i.e., 
anhedonia) may also have been ruled out as a potential endophenotype, but not conclusively.   
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1.3 AIMS OF THE CURRENT STUDY 
 
To build upon the literature and improve upon past studies’ methodological constraints, the 
present study examined a large, multigenerational, multiplex family sample to assess 
associations between behavior ratings of negative symptoms and genetic liability for 
schizophrenia among non-psychotic relatives of schizophrenia probands, to determine whether 
negative symptoms might be a potentially useful endophenotype in molecular genetic studies of 
schizophrenia.   
For these questions, multigenerational, multiplex family samples have several 
advantages. To the extent that schizophrenia risk alleles are more common among relatives in 
multiplex families than in singleton families, statistical power is increased. An additional benefit 
of the current study is that the inclusion of controls is not required. As the sample includes first 
through fourth-degree relatives, one will be able to determine a genetic correlation simply by 
comparing different degrees of relatives. This avoids the difficulty of ascertaining an 
appropriately equivalent control group. The current study also had approximately twice as many 
participants as any prior study of the question and examined other diagnoses in the relatives of 
probands, allowing for diagnostic specificity to be evaluated.   
The following hypotheses were examined:  
1) Negative symptoms will be more prevalent in schizophrenia probands than non-
psychotic relatives and controls.   
2) Heritabilities of negative symptoms should be significantly different from zero.   
3) The prevalence of negative symptoms should increase with the degree of genetic 
relationship to schizophrenia; in short, the genetic correlation between the negative 
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symptoms and the diagnosis of schizophrenia should be significant. If so, this implies 
some common familial causality between schizophrenia and negative symptoms.   
4) The prevalence of negative symptoms should not increase with the degree of genetic 
relationship to major depressive disorder probands (i.e., genetic correlation with 
depression should not be significant).   
5) The prevalence of negative symptoms should not increase with the degree of genetic 
relationship to substance abuse probands (i.e., genetic correlation with substance 
abuse should not be significant).   
 Additional questions were also examined regarding the measurement of negative 
symptoms. For each of the above questions, we examined both overall negative symptoms as well 
as individual negative symptoms (e.g., affective flattening, alogia, avolition) to determine which 
might be the most genetically correlated with schizophrenia and the other disorders. To our 
knowledge, no previous study has included as many relatives of schizophrenia patients or 
examined diagnostic specificity in this fashion.  
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2.0 METHODS 
 
 
2.1 PARTICIPANTS 
 
Probands and their relatives were recruited as part of a large, multisite schizophrenia multiplex 
family study (Gur et al., 2007; Tarbox et al., 2012). The 740 participants in the overall study 
included both European-American pedigree members from 43 multigenerational multiplex 
families and nonpsychotic control individuals demographically matched to the pedigree 
members. Written informed consent according to the guidelines of the University of Pittsburgh 
and University of Pennsylvania Institutional Review Boards was signed by all participants.  
 
2.1.1 Index probands 
 
Potential probands were identified through consumer and mental health organizations located in 
Pennsylvania, Delaware, Indiana, Kentucky, Michigan, New Jersey, Ohio, and West Virginia. 
Probands were at least 18 years old, European-American, met DSM-IV diagnostic criteria for 
schizophrenia or schizoaffective disorder, depressed type, and had at least one first-degree 
relative who also was at least 18 years old, European-American, met DSM-IV criteria for either 
schizophrenia or schizoaffective disorder, depressed type, and might be willing to participate. All 
diagnoses were established by consensus based on diagnostic interviews. Each proband was 
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additionally required to have at least 10 first- to fourth-degree relatives possibly willing to 
participate. Potential probands were excluded according to the following criteria: unable to 
provide signed informed consent, unwilling to provide consent to contact family members, 
psychosis due to a substance use disorder, medication, medical/neurological condition, or 
pervasive developmental disorder by DSM criteria, existence of a medical condition that may 
cause neurocognitive deficits, IQ < 70, or lack of proficiency in English. Thirty-six index 
probands met inclusion criteria and were enrolled in the study.  
 
2.1.2 Index relatives 
 
First- to fourth-degree relatives of each index proband who were 15 years of age or older at the 
time of recruitment and resided within the contiguous United States were eligible for 
participation. Potentially eligible relatives were identified by the probands and other enrolled 
family members and gave permission to be contacted by phone. Eligibility was established via a 
brief phone screening. Exclusion criteria were minimal: existence of a medical condition that 
may cause neurocognitive deficits, or lack of proficiency in English. In person interviews were 
scheduled with eligible relatives who agreed to participate.   
 
2.1.3 Pedigree Members Diagnoses 
 
Pedigree members meeting DSM criteria for schizophrenia or schizoaffective were considered 
“affected” (American Psychiatric Association, 2000). The remaining relatives were not 
diagnosed with either schizophrenia or schizoaffective disorder, depressed type, and thus were 
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“unaffected” pedigree members. The following additional hierarchical diagnostic groups were 
formed among the unaffected relatives: Other Psychoses; Cluster A (schizotypal personality-
disorder); Major Depressive Disorder; Substance Abuse; Miscellaneous; and No Diagnosis.   
 
2.1.4 Controls 
 
Non-psychotic, European-American individuals age 18 to 84, who did not have a first-degree 
relative with a psychotic disorder, were eligible for inclusion in the control group. Recruitment 
procedures implemented at the University of Pittsburgh were designed to achieve a 
representative control group that was on average matched on age, sex, and location of residence 
to the index relatives enrolled in the study. Potential control individuals residing in the regions 
from which the majority of index probands and relatives had been recruited were initially 
contacted through random digit dialing. Interested potential control individuals completed a 
telephone screening to assess the following exclusion criteria: they or a first-degree relative had 
been diagnosed with a schizophrenia spectrum disorder or other psychotic disorder, recent 
exacerbation of non-psychotic psychiatric symptoms (e.g., psychiatric hospitalization or a dose 
increase of psychiatric medication in the past month), electroconvulsive therapy in the past six 
months, treatment for alcohol or substance disorder in the past six months, medical condition 
that could produce psychiatric symptoms or neurocognitive deficits (e.g., Alzheimer’s disorder), 
history of head injury resulting in cognitive changes, or sensory or physical impairments that 
could interfere with completion of study measures.   
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2.2 ASSESSMENTS 
 
2.2.1 Diagnostic Assessment 
 
Lifetime, multiaxial diagnoses based on DSM-IV criteria were established by consensus 
conference by licensed psychiatrists and psychologists who were blind to subject identity and 
group status (proband, relative, control) (American Psychiatric Association, 2000). All 
interviews were conducted by trained interviewers with established reliability (kappa > 0.80) and 
under the supervision of the investigators. Reliability and training among interviewers was 
reviewed at semi-annual meetings. Interviewers were not blind to participant group status. All 
participants were administered the Diagnostic Interview for Genetic Studies 2.0 (DIGS) 
(Nurnberger et al., 1994) to assess current and lifetime psychiatric diagnoses and medical 
history. Furthermore, at least one relative of each proband was administered the Family 
Interview for Genetic Studies (FIGS) (Maxwell, 1992) to gather additional diagnostic 
information about family members. Considerable effort was made to interview each participant 
in person. On the rare occasions when an in-person appointment was not feasible, interviews 
were conducted by phone. If available, medical records were also reviewed.   
 
2.2.2. Scale for the Assessment of Negative Symptoms 
 
The Scale for the Assessment of Negative Symptoms (SANS) was used to measure negative 
symptoms. Developed by Andreasen (1983), it is divided into five subscales: Affective 
Flattening, Alogia, Avolition-Apathy, Anhedonia-Asociality, and Attention (Table 2). The 
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ratings were made by a trained interviewer following the DIGS interview, using a six-point scale 
(0 = not at all to 5 = severe).   
In addition to five global subscale ratings, summed subscales were also calculated by 
summing the individual items of each subscale (e.g., four items for Anhedonia) and dividing by 
the number of non-missing items for the subscale. A total global scale (average of global 
subscale ratings) and a total summed scale (average of summed subscale ratings) were also 
calculated. There was a total of 12 SANS scales analyzed: five global subscales, five summed 
subscales, one total global scale and one total summed scale.  
 
2.2.3 Depression-Cognitive Score  
 
A depression-cognitive score was also created based on the DIGS ratings for the current episode 
of major depression (items: guilt; worthlessness; suicidal thoughts; self-harming behaviors). This 
depression-cognitive scale was used as a covariate to minimize any potential confounding of 
negative symptoms by depression. 
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3.0 RESULTS 
 
 
3.1 SAMPLE CHARACTERISTICS 
 
3.1.1 Sample Selection and Attrition  
 
The initial step was the identification of individuals who had the complete SANS ratings and 
individuals with missing data. Seven hundred and forty individuals had a DIGS interview of 
whom five hundred individuals had at least one SANS rating. Individuals who were missing 13 
or more items from the SANS ratings (out of 25) were then removed.  
After this step, the sample was 493 total individuals, including 449 pedigree and 44 
control members. In one of the two sites, the SANS was not administered to any of the controls, 
explaining for the low number of available controls. Frequency distributions of each SANS 
rating were inspected for outliers and all scores were deemed valid.  
 
3.1.2 Demographics and Diagnoses 
 
A description of pedigree members with schizophrenia, pedigree members without 
schizophrenia, and controls in terms of sex, age, and education level is shown in Table 3. There 
were no significant overall differences observed among the samples on age 
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[F (2,490) = 2.506, p = 0.073] or sex [χ2 (2, N = 493) = 5.357, p = .069]. Not surprisingly, there 
was a significant difference among the samples on education [F (2,489) = 13.730, p = 0.001]. 
The affected pedigree group (those with the diagnosis of schizophrenia) had significantly fewer 
years of education than either the unaffected pedigree or controls. The affected pedigree group 
also had significantly fewer years of education than the controls.   
A breakdown by diagnosis is shown in Table 4. There was a total of 90 individuals 
diagnosed with schizophrenia. One hundred and eighty one individuals within the pedigree 
possessed other diagnoses; 178 individuals had no diagnoses. Among the 44 controls, 22 had 
diagnoses and 22 had none.   
 
3.1.3 Correlation of SANS Scales with Demographics 
 
The correlations of the SANS scales with age, sex, education, and depression score are reported 
in Table 5. Sex was correlated with nine scales (p < 0.05): Summed Total, Global Total, 
Summed Alogia, Global Alogia, Summed Avolition-Apathy, Global Avolition-Apathy, Summed 
Anhedonia-Asociality, Global Anhedonia-Asociality, and Global Attention with males being 
rated with higher negative symptoms. Age was positively associated only with the Summed 
Anhedonia-Asociality rating (p < 0.05). Education was negatively correlated with all of the 
scales (p < 0.01). The depression score was only correlated positively with the Global Affective 
Flattening rating (p < 0.05).   
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3.2 EXAMINATION OF SANS SCALES 
 
3.2.1 Intercorrelations of SANS Scales  
 
Correlations between each SANS scale in the pedigree sample are presented in Table 6. All 
scales were positively correlated with each of the other scale measures at a p-value of 0.01, 
including the global and summed scales. The Global Total and Summed Total scales were the 
highest correlated (r = 0.95). All summed scales were highly correlated with their corresponding 
global scales (r = 0.85 to 0.95).  
 
3.2.2 Group Mean Differences on SANS Scales  
 
A description of samples compared on each scale rating is shown in Table 7.  Members with 
schizophrenia, pedigree members without schizophrenia, and controls were compared on each 
SANS scale, with age, sex, and depression score as covariates. There were significant overall 
differences among samples for each scale (p < 0.0001). The schizophrenia group had 
significantly higher mean scores on each scale than both the pedigree non-schizophrenia and 
control group and there were significant differences between the non-schizophrenia pedigree and 
control groups on four scales: Global Total, Global Affective Flattening, Global Alogia, and 
Summed Attention (p < 0.05).  
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3.2.3 Heritability of SANS Scales  
 
All analyses of heritability and bivariate analyses of genetic correlation were completed using 
the SOLAR program (Sequential Oligogenic Linkage Analysis Routines) (Almasy & Blangero, 
1998). All dichotomous variables were modeled as threshold traits and all continuous variables 
were fit to a t-distribution. Total trait variance was separated into two components: (a) a 
component due to additive polygenic effects, and (b) a component due to the effects of random 
environmental factors. SOLAR used maximum likelihood estimation to a mixed effects model, 
and included fixed effects (known covariates) and variance components (genetic and random 
environmental effects). Shared environmental influences were assumed to be linearly related to 
the degree of genetic relatedness. In order to prevent ascertainment bias, analyses were 
conditioned on the trait values of the probands. These analyses were performed first in the 
sample of all pedigree members, and secondly among pedigree members without any diagnoses 
in order to minimize potential diagnostic effects on negative symptoms.   
Heritability (h2) indicates the proportion of trait variation that is due to genetic effects. As 
seen in Table 8, all scales showed significant heritability (h2 = 0.31 to 0.74, p = 0.0001) for the 
entire pedigree sample. In the more conservative sample of pedigree members without any 
diagnosis, all the scales except Global Attention and Summed Anhedonia-Asociality were 
significantly heritable (h2 = 0.26 to 0.73, p = 0.0001). In general, heritabilities were roughly 
similar in the two samples.  
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3.2.4 Genetic Correlations of SANS Scales and Schizophrenia  
 
Genetic correlations were calculated between negative symptoms and schizophrenia. Table 9 
presents the genetic (RG) correlations. Correlations were estimated controlling for covariates 
(age, sex, and depression score). For both the total and no diagnoses (except schizophrenia) 
samples, all negative symptoms displayed significant positive genetic correlations with the 
diagnosis of schizophrenia (RG = 0.29 to 0.92). The scales for Avolition-Apathy, both summed 
and global, showed the strongest correlations (RG = 0.75 for both, p = 0.001) in the total pedigree 
sample, as well as in the no diagnosis sample. In general, the genetic correlations were similar in 
the two samples. Such results indicate that even in a conservative sample, the more closely 
related to an individual with schizophrenia is, the more negative symptoms will be displayed.  
 
3.2.5 Genetic Correlations of SANS Scales and Major Depressive Disorder  
 
Subsequently, genetic correlations with major depressive disorder were estimated for each of the 
SANS scales in both the general pedigree sample and the sample of pedigree members with 
either diagnoses of major depressive disorder or no diagnoses. Correlations were estimated 
controlling for covariates (age, sex, and depression score). As reported in Table 10, unlike 
schizophrenia, major depressive disorder was not significantly genetically correlated with any of 
the SANS scales, and in fact showed non-significant trends for negative genetic correlations (RG 
= -1 to 0.23) in all the scales. Similar results were obtained within the conservative sample.  
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As such, the results reflect that relatives who are closely related to an individual with 
major depressive disorder are no more likely to display negative symptoms than those who are 
more distantly related.  
 
3.2.6 Genetic Correlations of SANS Scales and Substance Abuse  
 
The genetic correlations with substance abuse were also calculated for each of the SANS scales 
in both the general pedigree sample and the sample of pedigree members with either diagnoses 
of substance abuse or no diagnoses. Correlations were estimated controlling for covariates (age, 
sex, and depression score). Table 11 displays the data for substance abuse genetic correlations. In 
the general pedigree sample, substance abuse showed a negative correlation with SANS ratings 
(RG = -0.30 to 0.20), though not significant. Genetic correlations were slightly more positive in 
the conservative sample (RG = 0.46 to 1.0), but still not significant. Of all the scales, within the 
conservative sample, Summed Attention most closely approached significance (RG = 0.84, p = 
0.03); in the larger sample, no scale neared being significantly different.  
These results indicate that relatives who are closely related to an individual with 
substance abuse are no more likely to display negative symptoms than those who are more 
distantly related.  
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4.0 DISCUSSION 
 
 
The aims of this multigenerational, multiplex study were five-fold: 1) compare the prevalence of 
negative symptoms among probands, non-psychotic relatives, and controls, 2) estimate the 
heritabilities of negative symptoms, 3) calculate genetic correlations between individual negative 
symptom ratings and schizophrenia, 4) calculate genetic correlations between individual negative 
symptom ratings and major depressive disorder, and 5) calculate genetic correlations between 
individual negative symptom ratings and substance abuse. The study also served to examine and 
compare the different components of the SANS scale. The results are summarized as follows, 
and are elaborated upon below:  
1) Negative symptoms were more prevalent in schizophrenia probands than non-
psychotic relatives and controls.  
2) The majority of SANS scales, both summed and global, were highly heritable.  
3) Significant positive genetic correlations were observed between negative 
symptoms and the diagnosis of schizophrenia.   
4) Significant genetic correlations were not observed between negative symptoms 
and the diagnosis of major depressive disorder.   
5) Significant genetic correlations were not observed between negative symptoms 
and the diagnosis of substance abuse.   
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4.1 NEGATIVE SYMPTOM PREVALENCE 
 
 As predicted, negative symptoms were more prevalent in probands and pedigree members than 
control individuals.  
 
 
4.2 SANS SCALE SELECTION 
 
After calculating correlations between each individual SANS scales, it was observed that all the 
scales were associated with each other to a high degree. This suggested that either global or 
summed scales are adequate and sufficient for examining negative symptoms scores. The two 
total scales could also be used alone, or in conjunction with other scales. For example, an 
individual high in Affective Flattening is likely to also have a high rating in Alogia. 
Additionally, such correlations could be beneficial in predicting values for incomplete or missing 
data. No SANS scales were uncorrelated.  
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4.3 GENETIC LIABILITY TO SCHIZOPHRENIA 
 
4.3.1 Heritabilities and Genetic Correlations 
 
 The heritabilities of the SANS scales were largely significant, suggesting that the characteristics 
measured by the scales are influenced by genetic factors.  The heritability estimates were similar 
to those reported in previous studies (Chen et al., 2009).   
 Foremost, in both the total and the conservative sample, Summed and Global Avolition-
Apathy exhibited the highest genetic correlations with schizophrenia, suggesting that lack of 
persistence, energy, and motivation all share a percentage of their genetic effects with 
schizophrenia.   
 Though SANS scales were mainly genetically correlated with the diagnosis of 
schizophrenia, Summed Attention was not in the large sample (RG = 0.29, p = 0.06) and 
displayed the smallest significant correlation in the restricted sample (RG = 0.53, p = 0.001). It is 
unclear why this is so, considering the correlations between all of the scales.  
 As predicted, neither major depressive disorder nor substance abuse were significantly 
correlated with negative symptoms, although both displayed non-significant negative trends. 
This suggests that negative symptoms have a specific genetic connection to schizophrenia, rather 
than contributing to a more generalized association shared by numerous diagnoses.  
Being both heritable and strongly genetically correlated with schizophrenia in this 
sample, individual SANS scores may be potentially useful in genetic studies, especially 
Avolition-Apathy. Overall, it seems unlikely that genes contributing to liability to major 
depressive disorder or substance abuse also influence SANS scale scores. 
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4.3.2 Endophenotype Potential 
 
Returning to the original question, how do the results stack up to the concept and criteria of an 
endophenotype? In order to be beneficial in the understanding of the disorder, such phenotypes 
should be sensitive to specifically schizophrenia liability in particular, not a general signal of 
liability to psychopathology. As negative symptoms were genetically correlated with 
schizophrenia (and not major depressive disorder or substance abuse), the possibility as an 
endophenotype fits the definition well.  
 
 
4.4 LIMITATIONS 
 
As in all research, the current study did have limitations. For one, the genetic correlations with 
schizophrenia could potentially have been increased by the choice of multiplex pedigrees 
compared to simplex families. In addition, there could be a problem due to potential effects of 
the medications subjects were taking during data collection.  
As individuals with diagnoses of major depressive disorder or substance abuse also were 
relatives of schizophrenia patients, such results should be reproduced in a general population 
sample. As always, there is a possibility of selection bias, or an error in the selection of choosing 
the subjects, resulting in a non-random sample. However most results relied on relatives who 
were not biased. Another potential limitation was that of a wide age range. Although the average 
age of a relative was generally in the 40s and 50s, some subjects were quite young, and at risk 
for developing schizophrenia or another disorder. Thus, individuals could have been 
 26 
 
misclassified; if researchers had followed up these individuals, some could have developed 
schizophrenia. Such an error would inflate the results, and increase the chance of positive genetic 
correlations.  
Finally, as the study was not an adoption study, the separation of genetic and shared 
environmental effects rested on the assumption that shared environmental effects are not linear 
across relative classes.   
 
 
4.5 FUTURE DIRECTIONS 
 
The results of this study suggest that the numerous negative symptoms scales, but especially 
those for Avolition-Apathy, both summed and global, may be sensitive to genetic effects that 
increase risk for schizophrenia. Such genetic factors could be applied to a more thorough 
examination, such as linkage analyses, in order to evaluate the potential of such factors to aid in 
identifying specific genetic variants that contribute to the etiology of schizophrenia. For 
example, such genetic factors could be employed in genome-wide bivariate linkage analyses of 
schizophrenia, allowing the value of each factor to be discerned. Furthermore, one could 
examine the genetic intercorrelations among the SANS scales – if present, it would be suggest a 
genetic homogeneity across individual negative symptoms. 
Another potential avenue of research would be a comparison with positive or negative 
symptoms; perhaps a different dimension would demonstrate stronger genetic correlations and 
heritabilities, and thus serve as a better endophenotype.  
 
 27 
 
 
 
5.0 CONCLUSION 
 
 
The current study offered evidence of the use of negative symptoms as a potential 
endophenotype for schizophrenia.  This method is better than the initial use of GWAS as it is 
prioritizing: negative symptoms seems to affect a crucial aspect of the disorder, rather than 
examining all genes equally. The question of if endophenotypes will find more genetic variants 
depends on the penetrance.  
Overall, the study suggests the potential utility of negative symptoms as a candidate 
endophenotype with some diagnostic specificity in studies seeking to identify genetic risk 
variants contributing to schizophrenia. 
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APPENDIX 
 
 
TABLES  
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Table 1. Studies of Negative Symptoms among Relatives of Schizophrenia Patients 
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Table 2. Scale for the Assessment of Negative Symptoms1,2 
 
1 Affective Flattening or Blunting  
 1 Unchanged Facial Expression  
 2 Decreased Spontaneous Movements 
 3 Paucity of Expressive Gestures 
 4 Poor Eye Contact   
 5 Affective Nonresponsiveness  
 6 Inappropriate Affect  
 7 Lack of Vocal Inflections  
 8 Global Rating of Affective Flattening  
2 Alogia     
 9 Poverty of Speech   
 10 Poverty of Content of Speech  
 11 Blocking    
 12 Increased Latency of Response 
 13 Global Rating of Alogia  
3 Avolition-Apathy    
 14 Grooming and Hygiene  
 15 Impersistence at Work or School 
 16 Physical Anergia   
 17 Global Rating of Avolition-Apathy 
4 Anhedonia-Asociality   
 18 Recreational Interests and Activities 
 19 Sexual Activity   
 20 Ability to Feel Intimacy and Closeness 
 21 Relationships with Friends and Peers 
 22 Global Rating of Anhedonia-Asociality 
5 Attention    
 23 Social Inattentiveness  
 24 Inattentiveness During Mental Status Testing 
 25 Global Rating of Attention   
 
  
                                                 
1 Andreasen (1983). 
2 Ratings are measured on a 0 – 5 scale.  
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Table 3. Demographics of Pedigree and Control Participants 
 
  Number Sex  Age  Education 
   % male (number) Mean (St. Dev)  Mean (St. Dev) 
Affected Pedigree 90 58.89 (53) 46.13 (12.20)  12.37 (2.83)a 
Unaffected Pedigree 359 45.40 (163) 44.49 (18.52)  13.48 (2.97)b 
Control 44 45.45 (20) 50.41 (18.28)  15.16 (2.48)c 
P-value1 --- 0.069 0.073  0.0001 
                                                 
1 P-value for the overall ANOVA or chi-square analysis.  
a, b, c Groups not sharing superscripts are significantly different based on LSD test.   
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Table 4. Diagnostic Distribution among Pedigree and Control Participants 
 
   
Diagnosis1 
Pedigree Control 
 
Schizophrenia 90 0 
Other Psychoses 21 2 
ClusterA 18 0 
Major Depressive Disorder  47 9 
Substance Abuse 37 7 
Miscellaneous  58 4 
No Diagnosis  178 22 
Total 449 44 
 
                                                 
1 Diagnoses of schizophrenia, other psychoses, schizotypal personality-disorder (Cluster A), major depressive 
disorder, substance abuse, and miscellaneous are hierarchical. 
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Table 5. Correlations between Demographics and SANS Scales in the Pedigree Sample 
 
  Sex1 Age Education  
Depression 
Score  
Summed Total -0.148 b 0.011 -0.322b 0.027 
Global Total  -0.145 b -0.012 -0.311b 0.050 
Summed  Affective 
Flattening 
-0.068 -0.069 -0.302b 0.069 
Global Affective Flattening -0.081 -0.077 -0.263b 0.100 a 
Summed Alogia -0.095a 0.006 -0.258b 0.036 
Global Alogia  -0.154b -0.029 -0.243b 0.022 
Summed Avolition-Apathy -0.177b -0.007 -0.266b 0.033 
Global Avolition-Apathy -0.153b -0.022 -0.243b 0.047 
Summed Anhedonia-
Asociality 
-0.154b 0.089a -0.281b 0.018 
Global Anhedonia-Asociality -0.139b 0.073 -0.250b 0.048 
Summed Attention -0.066 0.032 -0.333b 0.005 
Global Attention  -0.082 0.016 -0.285b -0.005 
                                                 
1 Sex (male = 1, female = 2). 
a Correlation is significant at the 0.05 level (2-tailed). 
b Correlation is significant at the 0.01 level (2-tailed). 
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Table 6. Intercorrelations of SANS Scales 
                                                 
a Correlation is significant at the 0.01 level (2-tailed).  
 
 
  
Summed 
Total 
Global 
Total  
Summed  
Affect 
Global 
Affect 
Summed 
Alogia 
Global 
Alogia  
Summed 
Avolition 
Global 
Avolition 
Summed 
Anhedonia 
Global 
Anhedonia 
Summed 
Attention 
Global 
Attention  
Summed Total 
  0.956a 0.865a 0.816a 0.832a 0.792a 0.877a 0.846a 0.871a 0.821a 0.662a 0.703a 
Global Total  
0.956a   0.823a 0.861a 0.803a 0.833a 0.842a 0.854a 0.873a 0.840a 0.703a 0.774a 
Summed  Affective 
Flattening 0.865a 0.823a   0.881a 0.753a 0.723a 0.688a 0.667a 0.641a 0.613a 0.525a 0.552a 
Global Affective 
Flattening 0.816a 0.861a 0.881a   0.696a 0.725a 0.663a 0.676a 0.669a 0.648a 0.500a 0.543a 
Summed Alogia 
0.832a 0.803a 0.753a 0.696a   0.905a 0.610a 0.593a 0.597a 0.565a 0.617a 0.632a 
Global Alogia  
0.792a 0.833a 0.723a 0.725a 0.905a   0.594a 0.593a 0.597a 0.580a 0.595a 0.624a 
Summed Avolition-
Apathy 0.877a 0.842a 0.688a 0.663a 0.610a 0.594a   0.953a 0.707a 0.678a 0.549a 0.596a 
Global Avolition-
Apathy 0.846a 0.854a 0.667a 0.676a 0.593a 0.593a 0.953a   0.698a 0.688a 0.524a 0.575a 
Summed Anhedonia-
Asociality 0.871a 0.837a 0.64a 0.669a 0.597a 0.597a 0.707a 0.698a   0.932a 0.519a 0.570a 
Global Anhedonia-
Asociality 0.821a 0.840a 0.613a 0.648a 0.565a 0.580a 0.678a 0.688a 0.932a   0.490a 0.532a 
Summed Attention 
0.662a 0.703a 0.525a 0.500a 0.617a 0.595a 0.549a 0.521a 0.519a 0.490a   0.855a 
Global Attention  
0.703a 0.774a 0.552a 0.543a 0.632a 0.624a 0.596a 0.575a 0.570a 0.532a 0.855a   
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Table 7. Sample Differences on SANS Scales1 
                                                 
1 Covariates were sex, age and depression score.  
2  P-value for the overall ANOVA analysis.  
a, b, c Groups not sharing superscripts are significantly different based on LSD test.  
Sample 
 
 
 
 
 
 
 
  
Summed 
Total 
Global 
Total 
Summed  
Affective 
Flattening 
Global 
Affective 
Flattening 
Summed 
Alogia 
Global 
Alogia 
Summed 
Avolition-
Apathy 
Global 
Avolition-
Apathy 
Summed 
Anhedonia
-Asociality 
Global 
Anhedonia
-Asociality 
Summed 
Attention 
Global 
Attention 
mean  
(st. dev) 
mean 
 (st. dev) 
mean  
(st. dev) 
mean  
(st. dev) 
mean  
(st. dev) 
mean  
(st. dev) 
mean  
(st. dev) 
mean  
(st. dev) 
mean 
 (st. dev) 
mean  
(st. dev) 
mean  
(st. dev) 
mean 
 (st. dev) 
Affected 
Pedigree 
1.46 
(1.03)a 
1.81 
(1.17) a 
1.21 
(1.03) a 
1.91 
(1.32) a 
1.00 
(1.07) a 
1.39 
(1.35)  a 
1.78  
(1.29) a 
2.04 
(1.47) a 
2.09 
(1.40) a 
2.33  
(1.37) a 
1.47 
(1.38) a 
1.55 
(1.43) a 
Unaffected 
Pedigree  
0.31 
(0.53) b 
0.50 
(0.73) b 
0.27 
(0.56) b 
0.54 
(0.96) b 
0.26 
(0.56) b 
0.43 
(0.88) b 
0.32  
(0.73) b 
0.40 
(0.89) b 
0.53  
(0.89) b 
0.69  
(1.14) b 
0.55 
(0.95) b 
0.43 
(0.89) b 
Control 
 
0.15 
(0.29) b 
0.18 
(0.37) c 
0.11 
(0.29) b 
0.18 
(0.43) c 
0.08 
(0.21) b 
0.09 
(0.26) c 
0.16  
(0.50) b 
0.17 
(0.65) b 
0.34 
 (0.89) b 
0.37  
(0.92) b 
0.11 
(0.37) c 
0.12 
(0.39) b 
P-value2 
 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
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Table 8. Heritabilities of SANS Scales in the Pedigree Sample1 
 
 Pedigree Pedigree Without Diagnosis 
 Heritability P-value Heritability P-value 
Summed Total 0.53 0.0001 0.31 0.0001 
Global Total 0.62 0.0001 0.65 0.0001 
Summed  Affective Flattening 
0.43 0.0001 0.67 0.0001 
Global Affective Flattening 
0.52 0.0001 0.55 0.0001 
Summed Alogia 0.56 0.0001 0.26 0.0001 
Global Alogia 0.74 0.0001 0.35 0.0001 
Summed Avolition-Apathy 
0.45 0.0001 0.69 0.0001 
Global Avolition-Apathy 
0.48 0.0001 0.73 0.0001 
Summed Anhedonia-Asociality 
0.40 0.0001 0.36 0.5000 
Global Anhedonia-Asociality 
0.37 0.0001 0.28 0.0001 
Summed Attention 0.66 0.0001 0.64 0.0001 
Global Attention 0.31 0.0001 0.27 0.5000 
                                                 
1 Covariates were sex, age and depression score. 
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Table 9. Genetic Correlations of SANS Scales with Schizophrenia1 in the Pedigree Sample 
 
  
Pedigree Pedigree without Diagnosis 
RG P-value from 0 RG P-value from 0 
Summed Total 
0.61 0.001 0.84 0.001 
Global Total 
0.57 0.001 0.79 0.001 
Summed  Affective Flattening2 
0.58 0.001 0.78 0.001 
Global Affective Flattening2 
0.55 0.001 0.77 0.001 
Summed Alogia 
0.46 0.003 0.72 0.001 
Global Alogia 
0.69 0.003 0.69 0.001 
Summed Avolition-Apathy 
0.75 0.001 0.87 0.001 
Global Avolition-Apathy 
0.75 0.001 0.92 0.001 
Summed Anhedonia-Asociality2 
0.64 0.001 0.82 0.001 
Global Anhedonia-Asociality2 
0.59 0.001 0.73 0.001 
Summed Attention 
0.29 0.060 0.53 0.007 
Global Attention 
0.47 0.003 0.67 0.001 
                                                 
1 Dichotomized variable: Diagnosis/symptoms: absent = 0, present = 1. 
2  Was not evaluated with covariates (sex, age, and depression score) due to convergence failure. 
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Table 10. Genetic Correlation of SANS Scales with Major Depressive Disorder1 in the 
Pedigree Sample 
 
  
Pedigree Pedigree without Diagnosis 
RG P-value from 0 RG P-value from 0 
Summed Total 
-0.47 0.07 -0.49 0.33 
Global Total 
-0.27 0.26 -0.09 0.85 
Summed  Affective Flattening2 
-0.62 0.04 -0.48 0.52 
Global Affective Flattening2 
-0.34 0.22 0.01 0.99 
Summed Alogia 
-0.29 0.27 -0.90 0.47 
Global Alogia 
-0.35 0.21 -1.00 0.65 
Summed Avolition-Apathy 
-0.54 0.06 -0.27 0.52 
Global Avolition-Apathy 
-0.34 0.21 0.01 0.97 
Summed Anhedonia-Asociality2 
-0.29 0.37 -0.29 0.64 
Global Anhedonia-Asociality2 
-0.16 0.62 -0.27 0.61 
Summed Attention 
-0.27 0.32 -0.53 0.28 
Global Attention 
-0.16 0.56 0.23 0.80 
Substance Abuse  
-1 0.11 Convergence Failure 
                                                 
1 Dichotomized variable: Diagnosis/symptoms: absent = 0, present = 1. 
2 Was not evaluated with covariates (sex, age, and depression score) due to convergence failure. 
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Table 11. Genetic Correlation of SANS Scales with Substance Abuse1 in the Pedigree Sample 
 
  
Pedigree  Pedigree without Diagnosis 
RG P-value from 0 RG P-value from 0 
Summed Total 
-0.22 0.38 0.57 0.20 
Global Total 
-0.10 0.68 0.61 0.14 
Summed  Affective Flattening2 
-0.30 0.33 1.00 0.17 
Global Affective Flattening2 
-0.13 0.66 1.00 0.06 
Summed Alogia 
-0.18 0.50 1.00 0.37 
Global Alogia 
-0.05 0.87 1.00 0.35 
Summed Avolition-Apathy 
-0.23 0.40 0.51 0.08 
Global Avolition-Apathy 
-0.18 0.52 0.58 0.08 
Summed Anhedonia-Asociality2 
-0.18 0.59 0.48 0.28 
Global Anhedonia-Asociality2 
0.03 0.92 0.46 0.23 
Summed Attention 
0.20 0.41 0.84 0.03 
Global Attention 
0.03 0.90 0.90 0.22 
Major Depressive Disorder 
-1 0.11 Convergence Failure  
 
                                                 
1 Dichotomized variable: Diagnosis/symptoms: absent = 0, present = 1.  
2 Was not evaluated with covariates (sex, age, and depression score) due to convergence failure. 
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